Recent work on metabolic biomarkers for epithelial cancers has suggested that urinary levels of pteridines and modified nucleosides may be independently associated with increased risk of developing cancer. This study aimed to evaluate whether a novel composite panel of 28 pteridines and modified nucleosides can afford greater accuracy as a risk stratification model. First, an observational case-control clinical study involving 330 post-menopausal women with newly diagnosed breast cancers and matched controls was conducted to optimize the biomarker profile for breast cancer risk assessment. The association between adjusted biomarker levels with breast cancer risk was evaluated using logistic regression models from which odds-ratios and receiver-operation characteristic curves could be computed. Second, the disease specificity of the optimized composite biomarker panel was determined by characterizing its association with several common cancers of epithelial origin, including prostate, bladder, kidney, and lung cancers. Patients with newly diagnosed cancers (<i>N </i>= 130 each cancer) and an equal number of matched controls (650 total study participants) were recruited in a case-consecutive manner across China. Multivariate principal component analyses were used to determine group differences among individual biomarkers to discover possible cancer fingerprinting applications, while group-wise comparisons were made using nonparametric Kruskal-Wallis and Mann-Whitney analyses. Optimized risk stratification models for each cancer type were produced from logistic regression models. Our findings suggest that the combination of urinary pteridines and modified nucleosides can provide improved risk stratification for women with breast cancer and that elevated levels of both biomarker types occur in several common epithelial cancers, which may be differentiated using composite biomarker panels. The detailed findings of the study will be presented at the symposium.<br/>

Noninvasive characterization of epithelial cancers using a composite panel of urinary pteridines and modified nucleosides

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.